Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Glenmark Pharmaceuticals won Innovation of the Year award
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
ICICI Direct gives a preview on the earnings narrative for Q3FY22
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Flattish volume growth and subdued new launches were key factors for last month
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)